The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Open accessPreprint — published as 10.3389/fphar.2021.683296
Abstract
Background: No clinically proven effective antiviral strategy exists for the epidemic Coronavirus Disease 2019 (COVID-19). Methods: We conducted a prospective, randomized, controlled, open-label multicenter trial involving adult patients with COVID-19. Patients were randomly assigned in a 1:1 ratio to receive conventional therapy plus Umifenovir (Arbidol) (200mg*3/day) or Favipiravir (1600mg*2/first day followed by 600mg*2/day) for 10 days. The primary outcome was clinical recovery rate of Day 7. Latency to relief for pyrexia and cough, the rate of auxiliary oxygen therapy (AOT) or noninvasive mechanical ventilation (NMV) were the secondary outcomes. Safety data were collected for 17 days. Results: 240 enrolled COVID-19 patients underwent randomization; 120 patients were assigned to receive Favipiravir (116 assessed), and 120 to receive Arbidol (120 assessed). Clinical recovery rate of Day 7 does not significantly differ between Favipiravir group (71/116) and Arbidol group (62/120) (P=0.1396, difference of recovery rate: 0.0954; 95% CI: -0.0305 to 0.2213). Favipiravir led to shorter latencies to relief for both pyrexia (difference: 1.70 days, P<0.0001) and cough (difference: 1.75 days, P<0.0001). No difference was observed of AOT or NMV rate (both P>0.05). The most frequently observed Favipiravir-associated adverse event was raised serum uric acid (16/116, OR: 5.52, P=0.0014). Conclusions: Among patients with COVID-19, Favipiravir, compared to Arbidol, did not significantly improve the clinically recovery rate at Day 7. Favipiravir significantly improved the latency to relief for pyrexia and cough. Adverse effects caused Favipiravir are mild and manageable. This trial is registered with Chictr.org.cn (ChiCTR2000030254).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The subgroup effect is consistent with evidence from other meta-analyses.36”
From Drug treatments for covid-19: living systematic review and network meta-analysis (2020) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citation[Asymptomatic infection of COVID-19 and its challenge to epidemic prevention and control].
Gao, X., Chen, W., Guo, L., Zhang, T.-Z., & Zhao, H.-Q. (2020) · Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi · doi:10.3760/cma.j.cn112338-20200427-00659 · Cited by 28,519 · cited 2×
“In China, although arbidol has been recommended in The Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme (6th trial version) [8].”
BackgroundZhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263 · cited 1×
“The clinical studies of some drugs (human interferon alfa-2b, ribavirin, chloroquine phosphate, lopinavir and arbidol) were currently undergoing to test the efficacy and safety of these drugs in the treatment of COVID-19 [7].”
BackgroundSelf-citationWang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148 · cited 4×
“or with Child-Pugh C; (3) Severe/critical patients whose expected survival time <48”
BackgroundMethodInfluentialSelf-citationLa certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Self-citationAlberca, G., Fernandes, I. G., Sato, M., et al. (2020) · Frontiers for Young Minds · doi:10.3389/frym.2020.00074 · Cited by 8,821
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Dong, L., Hu, S., & Gao, J. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.01012 · Cited by 1,391
Zhang, H., Kang, Z., Gong, H., Xu, D., Wang, J., Li, Z., Cui, X., Xiao, J., Meng, T., Zhou, W., et al. (2020) · doi:10.1101/2020.01.30.927806 · Cited by 658 · cited 1×
“6171) and digestive tract reactions (nausea, anti-acid, flatulence [10]) (14 [11.”
BackgroundIn Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.977-981.2002 · Cited by 508
The mechanism of resistance to favipiravir in influenza
Goldhill, D., Velthuis, A. T., Fletcher, R. A., et al. (2018) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1811345115 · Cited by 285 · cited 1×
“promising antiviral drug targeting the influenza viral RNA-dependent RNA polymerase (RdRP) [6].”
BackgroundShi, L., Xiong, H., He, J., Deng, H., Li, Q., Zhong, Q., Hou, W., Cheng, L., Xiao, H., & Yang, Z. (2007) · Archives of Virology · doi:10.1007/s00705-007-0974-5 · Cited by 135 · cited 1×
“hours; (4) Female in pregnancy; (5) HIV infection; (6) Considered unsuitable by researchers.”
BackgroundArbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses
Hulseberg, C. E., Fénéant, L., Wijs, K. S.-D., Kessler, N., Nelson, E. A., Shoemaker, C. J., Schmaljohn, C. S., Polyak, S. J., & White, J. M. (2019) · Journal of Virology · doi:10.1128/jvi.02185-18 · Cited by 128
Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR).
Pshenichnaya, N., Bulgakova, V., Lvov, N., et al. (2019) · Терапевтический архив · doi:10.26442/00403660.2019.03.000127 · Cited by 45
Cited by
Sorted by citations
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,442
“9 In severe illness, one uncontrolled study of five patients given convalescent plasma suggested a possible benefit, although the patients already had detectable anti-SARS-CoV-2 neutralising antibodies before receipt of the plasma.”
BackgroundSelf-citationPharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,392
“Male 30 (73) 67 (68) 75 (54) 35 (67) 9 (50) 8 (67) 637 (58)”
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Self-citationStructure of the RNA-dependent RNA polymerase from COVID-19 virus
Gao, Y., Yan, L., Huang, Y., Liu, F., Zhao, Y., Cao, L., Wang, T., Sun, Q., Ming, Z., Zhang, L., et al. (2020) · Science · doi:10.1126/science.abb7498 · Cited by 1,614
Self-citationDrug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Metadata
- Authors
- Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., Luo, Y., Ju, L., Zhang, J., & Wang, X.
- Affiliations
- Zhongnan Hospital of Wuhan University (CN)
- Peking University (CN)
- Huazhong University of Science and Technology (CN)
- Hubei Zhongshan Hospital (CN)
- Corresponding author
- Wang, Xinghuan
- ORCID
- Venue
- Frontiers in Pharmacology
- Publisher
- openRxiv
- Published
- 2020-03-20
- Volume
- 12
- Pages
- 683296-683296
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC8443786
- OpenAlex
- W3197627421
- Cited by
- 852
- References
- 12
- Citations by year
- 2026: 2 · 2025: 18 · 2024: 32 · 2023: 54 · 2022: 136 · 2021: 231 · 2020: 379
- FWCI
- 36.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- medRxiv (acceptedVersion)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Capital Medical University
- Huazhong University of Science and Technology
- Tongji University
- Wuhan University
- Wuhan University of Science and Technology
- Shanghai University of Traditional Chinese Medicine
- Longhua Hospital Shanghai University of Traditional Chinese Medicine
- Science and Technology Department of Hubei Province
- National Key Research and Development Program of China (2020YFC0844400)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Keywords
- favipiravir, umifenovir, arbidol, COVID-19 pandemic, antiviral therapy, clinical recovery, non-invasive ventilation, mechanical ventilation, serum uric acid, drug safety, SARS-CoV-2, adults, randomized trial comparison, adverse events
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
